MA34025B1 - Polypeptides se liant au bêta-a - Google Patents

Polypeptides se liant au bêta-a

Info

Publication number
MA34025B1
MA34025B1 MA35176A MA35176A MA34025B1 MA 34025 B1 MA34025 B1 MA 34025B1 MA 35176 A MA35176 A MA 35176A MA 35176 A MA35176 A MA 35176A MA 34025 B1 MA34025 B1 MA 34025B1
Authority
MA
Morocco
Prior art keywords
beta
amyloid
binding
polypeptides binding
biparatubic
Prior art date
Application number
MA35176A
Other languages
Arabic (ar)
English (en)
Inventor
John E Park
Cornelia Dorner-Ciossek
Stefan Hoerer
Lothar Kussmaul
Martin Lenter
Katharina Zimmermann
Gerald Beste
Toon Laeremans
Pascal Merchiers
Jo Vercammen
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA34025B1 publication Critical patent/MA34025B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)

Abstract

)l'invention concerne des polypeptides de liaison bêta-amyloïdes biparatopiques, et plus spécifiquement des polypeptides de liaison bêta-amyloïdes biparatopiques comprenant au moins deux domaines variables uniques d'immunoglobuline se liant à différents épitopes de bêta-amyloïde. L'invention concerne également des séquences spécifiques de ces polypeptides, leurs procédés de production et des procédés d'utilisation de ceux-ci, notamment des méthodes de traitement de maladies comme la maladie d'alzheimer.
MA35176A 2010-03-03 2011-03-02 Polypeptides se liant au bêta-a MA34025B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10155339 2010-03-03
PCT/EP2011/053090 WO2011107507A1 (fr) 2010-03-03 2011-03-02 Polypeptides de liaison bêta-amyloïdes biparatopiques

Publications (1)

Publication Number Publication Date
MA34025B1 true MA34025B1 (fr) 2013-02-01

Family

ID=42227600

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35176A MA34025B1 (fr) 2010-03-03 2011-03-02 Polypeptides se liant au bêta-a

Country Status (24)

Country Link
US (3) US8337845B2 (fr)
EP (1) EP2542579A1 (fr)
JP (2) JP5826194B2 (fr)
KR (1) KR20130010114A (fr)
CN (1) CN102781962B (fr)
AP (1) AP2012006359A0 (fr)
AR (1) AR080446A1 (fr)
AU (1) AU2011222980B2 (fr)
BR (1) BR112012022102A2 (fr)
CA (1) CA2788275A1 (fr)
CL (1) CL2012002095A1 (fr)
CO (1) CO6592094A2 (fr)
EA (1) EA201201227A1 (fr)
EC (1) ECSP12012184A (fr)
MA (1) MA34025B1 (fr)
MX (1) MX2012009460A (fr)
NZ (1) NZ601117A (fr)
PE (1) PE20130527A1 (fr)
PH (1) PH12012501744A1 (fr)
SG (1) SG183369A1 (fr)
TN (1) TN2012000434A1 (fr)
TW (1) TW201144437A (fr)
UY (1) UY33253A (fr)
WO (1) WO2011107507A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012501744A1 (en) 2010-03-03 2021-08-09 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
WO2012042026A1 (fr) 2010-09-30 2012-04-05 Ablynx Nv Matières biologiques associées à c-met
US11644471B2 (en) * 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
LT3466972T (lt) 2011-06-23 2026-06-25 Ablynx Nv Serumo albuminą surišantys baltymai
CA3141978A1 (fr) 2011-06-23 2012-12-27 Ablynx Nv Techniques permettant de predire, detecter et reduire une interference proteinique specifique dans des dosages impliquant des domaines variables uniques d'immunoglobuline
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
CN104159922B (zh) * 2012-01-10 2018-03-02 比奥根Ma公司 对转运治疗性分子穿过血脑屏障的增强
WO2015006337A2 (fr) 2013-07-08 2015-01-15 Nanjingjinsirui Science & Technology Biology Corporation Compositions et procédés permettant d'augmenter la demi-vie d'une protéine dans un sérum
LT3248986T (lt) 2014-05-16 2022-03-25 Ablynx Nv Imunoglobulino kintami domenai
IL318433A (en) * 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
CN107074961A (zh) * 2014-11-03 2017-08-18 默克专利股份公司 用于生成双特异性鲨鱼可变抗体结构域的方法及其用途
US20170335324A1 (en) 2014-11-12 2017-11-23 The General Hospital Corporation Methods for treating neurodegenerative diseases
CN104558172A (zh) * 2015-01-04 2015-04-29 东南大学 一种针对β淀粉样蛋白的单域重链纳米抗体及其应用
EP3253790A4 (fr) * 2015-02-06 2018-07-25 University of Maryland, Baltimore Agents de liaison octamères tétraspécifiques et anticorps anti-toxine a et anti-toxine b de clostridium difficile pour le traitement de l'infection à c. difficile
CN112649537B (zh) * 2015-04-28 2024-03-29 深圳翰宇药业股份有限公司 多肽混合物高效液相色谱分析方法
PT3383425T (pt) 2015-12-04 2020-10-07 Boehringer Ingelheim Int Polipéptidos biparatópicos que antagonizam a sinalização wnt em células tumorais
SG10201607778XA (en) * 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
US11033636B2 (en) 2017-05-31 2021-06-15 Boehringer Ingelheim International Gmbh Polypeptides antagonizing Wnt signaling in tumor cells
CA3070253A1 (fr) * 2017-07-19 2019-01-24 Vib Vzw Agents de liaison a la l'albumine serique
US20200392512A1 (en) * 2018-02-26 2020-12-17 Ablynx N.V. Nucleotide sequences encoding peptide linkers
US12259395B2 (en) 2018-08-17 2025-03-25 Ab Studio Inc. Catabodies and methods of use thereof
MA54070A (fr) * 2018-10-29 2021-09-08 Biogen Ma Inc Variants fc5 humanisés et stabilisés pour l'amélioration du transport à travers la barrière hémato-encéphalique
CN111334480B (zh) * 2020-05-18 2020-09-01 苏州仁端生物医药科技有限公司 一种分泌抗Aβ1-42单克隆抗体的杂交瘤细胞株及其应用
AU2021310926A1 (en) 2020-07-23 2023-03-23 Othair Prothena Limited Anti-abeta antibodies
WO2022072255A1 (fr) * 2020-09-30 2022-04-07 Merck Sharp & Dohme Corp. Protéines de liaison et fragments de liaison à l'antigène de celles-ci se liant à abêta
TW202246334A (zh) * 2021-02-02 2022-12-01 美商美國禮來大藥廠 Gitr拮抗劑及其使用方法
CN113686235B (zh) * 2021-08-16 2022-09-16 中国科学院力学研究所 一种基于纳米孔过孔电流估计蛋白质构象形貌特征的方法
US20240415974A1 (en) 2022-12-23 2024-12-19 Ablynx N.V. Protein-based conjugation carriers
IL322519A (en) 2023-02-17 2025-10-01 Ablynx Nv Polypeptides that bind to the neonatal fc receptor
CN120025456B (zh) * 2024-03-13 2025-11-07 寻济生物科技（北京）有限公司 一种抗vegfa融合构建体及其制备方法和应用
CN120919292A (zh) * 2025-08-04 2025-11-11 首都医科大学宣武医院 用于预防或治疗阿尔茨海默病的Aβ-Tau多表位疫苗及其用途

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
EP0739981A1 (fr) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
CA2441903C (fr) 2000-05-26 2012-07-31 National Research Council Of Canada Anticorps cibles sur le cerveau a domaine unique, derives d'anticorps de lama
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
JP4303105B2 (ja) 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
JP4123856B2 (ja) 2001-07-31 2008-07-23 日油株式会社 生体関連物質の修飾剤およびポリオキシアルキレン誘導体の製造方法
WO2003059934A2 (fr) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Proteines de fusion d'albumine
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
FR2846667B1 (fr) 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
NZ540194A (en) * 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1558645B1 (fr) 2002-11-08 2011-07-27 Ablynx N.V. Anticorps a domaine unique stabilises dans une composition pharmaceutique pour inhalation
ATE444984T1 (de) 2002-12-31 2009-10-15 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
JP5087274B2 (ja) 2003-06-30 2012-12-05 ドマンティス リミテッド ポリペプチド
PT1687338E (pt) 2003-11-07 2011-01-20 Ablynx Nv Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações
SI2336147T1 (sl) 2003-12-17 2014-08-29 Janssen Alzheimer Immunotherapy Konjugati nosilcev a beta imunogenih peptidov in postopki izdelave istih
WO2006040153A2 (fr) 2004-10-13 2006-04-20 Ablynx N.V. Nanocorps™ contre la proteine beta-amyloide et polypeptides les renfermant pour le traitement de maladies degeneratives neurales, telles que la maladie d'alzheimer
CN101076543A (zh) * 2004-10-13 2007-11-21 阿布林克斯公司 用于治疗和诊断变性神经疾病如阿尔茨海默症的单结构域骆驼抗淀粉样蛋白β的抗体以及包含它的多肽
US20060257396A1 (en) 2004-12-15 2006-11-16 Jacobsen Jack S Abeta antibodies for use in improving cognition
ES2396555T3 (es) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
EP1838348B1 (fr) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Anticorps du peptide beta-amyloide humanises utilises dans l'amelioration de la cognition
WO2006081171A1 (fr) 2005-01-24 2006-08-03 Amgen Inc. Anticorps anti-amyloide humanise
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
LT2444424T (lt) * 2005-05-20 2018-10-25 Ablynx N.V. Pagerintos tm nanodalelės, skirtos agregacijos sąlygotų sutrikimų gydymui
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR20140053410A (ko) * 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
JP2009508521A (ja) 2005-09-23 2009-03-05 アカデミッシュ ジーケンハイス レイデン タンパク凝集に関連する疾患の診断予防及び治療のためのｖｈｈ
CA2632828C (fr) 2005-12-12 2012-07-10 F. Hoffmann-La Roche Ag Anticorps contre la beta-amyloide ayant subi une glycosylation dans la region variable
NZ568012A (en) 2005-12-12 2012-07-27 Ac Immune Sa A beta 1-42 specific monoclonal antibodies with therapeutic properties
KR101263294B1 (ko) 2006-03-30 2013-06-04 글락소 그룹 리미티드 아밀로이드­베타 펩티드에 대한 항체
RU2498999C2 (ru) 2006-07-14 2013-11-20 Ац Иммуне Са Гуманизированное антитело к амилоиду бета
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
JP2010511397A (ja) 2006-12-05 2010-04-15 アブリンクス エン．ヴェー． 血清タンパク質と結合可能なペプチド
CN101553504A (zh) 2006-12-11 2009-10-07 豪夫迈·罗氏有限公司 Aβ抗体胃肠外制剂
US8907065B2 (en) * 2006-12-15 2014-12-09 Ablynx N.V. Polypeptides that modulate the interaction between cells of the immune system
WO2008088983A1 (fr) 2007-01-18 2008-07-24 Eli Lilly And Company Aβ pégylé-fab
EP1978035A1 (fr) 2007-04-05 2008-10-08 Hans-Knöll-Institut Leibniz-Institut für Naturstoff-Forschung Anticorps anti-amyloïdes et leur utilisation dans le diagnostic et la thérapie des maladies amyloïdes
MX2009012650A (es) * 2007-05-24 2010-02-18 Ablynx Nv Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
PE20090329A1 (es) 2007-05-30 2009-03-27 Abbott Lab Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
HRP20150086T1 (xx) 2007-06-12 2015-02-27 Ac Immune S.A. Humanizirana antitijela za beta amiloid
CA2690434C (fr) 2007-06-12 2018-05-22 Ac Immune S.A. Anticorps monoclonal anti-amyloide beta
EP2008666A1 (fr) * 2007-06-29 2008-12-31 Institut Pasteur Utilisation d'anticorps VHH pour la préparation de vecteurs de peptide pour fournir une substance d'intérêt et leurs applications
EP2009445A1 (fr) 2007-06-29 2008-12-31 Institut Pasteur Utilisation d'anticorps à domaine simple de chaînes pour détecter une formule oligomérique d'un peptide amyloide bêta et ses applications
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
CN101883792B (zh) 2007-10-29 2014-08-27 基因创新有限公司 特异于β-淀粉状蛋白肽的新抗体以及其用作诊断剂或药物的用途
CA2706425A1 (fr) * 2007-11-27 2009-06-04 Ablynx N.V. Procede d'obtention de produits de construction de polypeptide comprenant au moins deux anticorps a domaine unique
US20110091462A1 (en) 2008-03-05 2011-04-21 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making and uses thereof
CA2721202A1 (fr) 2008-04-17 2009-10-22 Hilde Adi Pierrette Revets Peptides capables de se lier a des proteines seriques et composes, constructions et polypeptides les comprenant
KR20110016959A (ko) * 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
PH12012501744A1 (en) 2010-03-03 2021-08-09 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides

Also Published As

Publication number Publication date
TN2012000434A1 (en) 2014-01-30
HK1175184A1 (en) 2013-06-28
CL2012002095A1 (es) 2012-10-19
AR080446A1 (es) 2012-04-11
UY33253A (es) 2011-09-30
JP5826194B2 (ja) 2015-12-02
MX2012009460A (es) 2012-09-12
CO6592094A2 (es) 2013-01-02
PE20130527A1 (es) 2013-05-09
WO2011107507A1 (fr) 2011-09-09
BR112012022102A2 (pt) 2017-01-10
AP2012006359A0 (en) 2012-08-31
US9211330B2 (en) 2015-12-15
PH12012501744A1 (en) 2021-08-09
CN102781962B (zh) 2014-12-10
TW201144437A (en) 2011-12-16
AU2011222980A1 (en) 2012-08-02
US8337845B2 (en) 2012-12-25
EP2542579A1 (fr) 2013-01-09
JP2015180691A (ja) 2015-10-15
US20130017209A1 (en) 2013-01-17
SG183369A1 (en) 2012-09-27
CN102781962A (zh) 2012-11-14
AU2011222980B2 (en) 2016-08-11
CA2788275A1 (fr) 2011-09-09
KR20130010114A (ko) 2013-01-25
US8614308B2 (en) 2013-12-24
ECSP12012184A (es) 2012-10-30
US20120058118A1 (en) 2012-03-08
US20140030275A1 (en) 2014-01-30
NZ601117A (en) 2014-06-27
JP2013520974A (ja) 2013-06-10
EA201201227A1 (ru) 2013-04-30

Similar Documents

Publication Publication Date Title
UA110470C2 (ru) Антидот антикоагулянта
EP2569330A4 (fr) Variants de la chlorotoxine, conjugués, et leurs méthodes d'utilisation
CY1122101T1 (el) Τροποποιημενα πολυπεπτιδια ρελαξινης και χρησεις αυτων
CY1122978T1 (el) Αντισωματα εναντι-vla-4
BR112013010834A2 (pt) polipeptídeos fator ix modificados e usos dos mesmos
EA201200617A1 (ru) Полимеры на основе циклодекстрина для доставки лекарственных средств
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
EA201170242A1 (ru) Модифицированные бычьи полипептиды g-csf и их применение
EA201101165A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ Toll-ПОДОБНЫХ РЕЦЕПТОРОВ
MX2011011925A (es) Anticuerpos triespecificos o tetraespecificos.
MA32190B1 (fr) Anticorps dirigés contre l'angiopoïétine 1 et l'angiopoïétine 2 et leur utilisation
UA104459C2 (uk) Антитіла проти fgfr3 і способи їх застосування
PH12013500500A1 (en) Fused heteroaryls and their uses
IL221278B (en) Chlorotoxin polypeptides and conjugates and uses thereof
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
UA112416C2 (uk) Антитіло до fap і способи його застосування
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
UA104005C2 (ru) 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
IL221205A0 (en) Antibody drug conjugates (adc) that bind to 161p2f10b proteins, compositions comprising the same and uses thereof
EA201170227A1 (ru) Имидазолкарбоксамиды
DOP2012000188A (es) Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus metodos de empleo
BR112013003536A2 (pt) composição, e utilização de uma composição.
EA201290541A1 (ru) Модифицированные бычьи соматотропиновые полипептиды и их применение
EA201290542A1 (ru) Модифицированные свиные соматотропиновые полипептиды и их применение
MA32321B1 (fr) Pregn-4-en-21, 17 carbolactones substitués sur le noyau c, et préparations pharmaceutiques contenant ces derniers